Abstract 768P
Background
The duration of progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer after response to platinum-based therapy is significantly longer with poly (ADP-ribose) polymerase inhibitors (PARPi). Unfortunately, after initial disease control, resistance to PARPi always occurs at some point. AsiDNA™ is a first-in-class DNA damage repair (DDR) inhibitor designed to prevent the repair of DNA damage in tumor cells. It is an oligonucleotide that mimics DNA double strand breaks, producing a false signal noise which acts as a decoy to disrupt the DDR at the “real” sites of DNA damage. The objective was to reverse acquired resistance to PARPi.
Methods
Patients (pts) who received a PARPi (niraparib, olaparib or rucaparib) in maintenance after platinum-based therapy for at least 6 months and who had an isolated increase of CA125 according to Rustin criteria without RECIST progression were includable. Part A: to assess the feasibility of the association of AsiDNA™ 600 mg in a IV weekly perfusion (higher active dose) + PARPi (last dose taken by the patient before entering the study) Part B: to assess the preliminary efficacy on CA-125 (decrease of 50%). Evaluation was to be done at 10, 15, 20 and 25 pts.
Results
6 patients were included in the dose de-escalation part. No DLT was observed (no related gr 3-4 AE). No more gr 3-4 AE was observed during the treatment of the 10 patients. Among the 10 patients evaluable for efficacy, none had a CA125 response. However, according to RECIST criteria, there were 6 pts with a stable disease, 1 with complete response and 3 with progressive disease. Study was stopped after 12 pts (the company stopped the fabrication of AsiDNA™ for new pts).
Conclusions
AsiDNA in addition to PARPi in pts with biological progression under PARPi is safe, and stabilization (> 6 months) has been observed in 3 pts.
Clinical trial identification
EudraCT 2020-000825-18.
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy Cancer campus.
Funding
ONXEO.
Disclosure
P. Pautier: Financial Interests, Personal, Advisory Board, 2015, 2022: PharmaMar; Financial Interests, Institutional, Advisory Board, 2020 : Roche, Clovis; Financial Interests, Institutional, Advisory Board, 2021 : AstraZeneca; Financial Interests, Personal, Advisory Board, 2019-2020: AstraZeneca; Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Personal, Advisory Board, 2018-2019: Roche; Financial Interests, Institutional, Advisory Board, 2022: MSD; Financial Interests, Personal and Institutional, Research Grant: PharmaMar; Financial Interests, Research Grant: ONXEO. F. Bazan: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Novartis, Eisai, Menarini; Financial Interests, Personal, Invited Speaker: AstraZeneca. A. Leary: Financial Interests, Personal, Advisory Board: Zentalis; Financial Interests, Personal, Invited Speaker, Educational: GSK, Medscape; Financial Interests, Personal, Writing Engagement, Educational: Onko+; Financial Interests, Institutional, Other, Steering committee: MSD; Financial Interests, Institutional, Advisory Board: GSK, AZ, Clovis, Ability Pharma, MSD, Merck Serono, Apmonia, Blueprint; Financial Interests, Institutional, Invited Speaker, Educational: Kephren publishing; Financial Interests, Institutional, Other, Consultancy: Orion; Financial Interests, Institutional, Invited Speaker: AZ, Clovis; Financial Interests, Personal, Other, Consultancy: GLG; Financial Interests, Institutional, Research Grant, PI translational research: ARCAGY-GINECO, Sanofi, AZ; Financial Interests, Institutional, Funding, CI clinical trial: AZ; Financial Interests, Institutional, Research Grant, Int CI clinical trial: OSE Immuno; Financial Interests, Institutional, Funding, PI clinical trial: Agenus, BMS, Iovance, GSK; Financial Interests, Institutional, Funding, PI 5 clinical trials: Roche; Financial Interests, Institutional, Funding, PI 2 clinical trials: AZ; Financial Interests, Institutional, Funding, PI 3 clinical trials and steering committee: MSD; Non-Financial Interests, Institutional, Other, Academic research project: Owkin, LXRepair; Non-Financial Interests, Personal, Proprietary Information, IDMC member: Clovis; Non-Financial Interests, Personal, Proprietary Information, IDMC chair: Pfizer; Non-Financial Interests, Member: GCIG. All other authors have declared no conflicts of interest.
Resources from the same session
638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 11
641P - Phase I/II study of the EP4 antagonist CR6086 combined with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Filippo Pietrantonio
Session: Poster session 11
642P - A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
Presenter: Jiuwei Cui
Session: Poster session 11
643P - A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201)
Presenter: Yongjun Cha
Session: Poster session 11
645P - A phase Ib dose escalation study of binimetinib plus mFOLFIRI in patients with metastatic RAS mutated colorectal cancer
Presenter: Vaia Florou
Session: Poster session 11
646P - Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)
Presenter: Andrew Hendifar
Session: Poster session 11
647P - Patient-derived xenograft approach to explore differential responses to diet dependent on genotypic or phenotypic characteristics of colorectal cancer
Presenter: Giulia Rizzo
Session: Poster session 11